Multiple sclerosis (MS) manifests in various subtypes, with the bulk of disability occurring among individuals with progressive disease. According to Dr. Fred Lublin, the primary drivers of burden in MS are motor dysfunction and cerebellar dysfunction, and there are numerous facets that account for the growing burden of the neurological condition. Dr. Gary Owens noted that the economic burden of MS can really be categorized into 3 phases: Phase 1 is the cost burden associated with initial presentation and the ensuing, intense diagnostic evaluation period; Phase 2 is comprised of diagnosed patients receiving disease-modifying treatments; and Phase 3 consists of patients with progressive disease and the expenditures associated with chronic care.
RFK Jr Claims HHS Has Not Fired Working Scientists, Canceled Lifesaving Research
May 15th 2025Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen